Clinical Research Services Contract

To provide services in respect of conducting a multinational Phase II study in non-cystic fibrosis BE patients, sponsored by Novartis, across Europe.

United Kingdom-Belfast: Research services

2020/S 017-036971

Contract notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses

Official name: Queen’s University Belfast
Postal address: University Road
Town: Belfast
NUTS code: UKN06
Postal code: BT7 1NN
Country: United Kingdom
Contact person: Pamela Rodgers
E-mail: pamela.rodgers@qub.ac.uk
Telephone: +44 2890973026

Internet address(es):Main address: https://www.qub.ac.uk/directorates/FinanceDirectorate/visitors/procurement

Address of the buyer profile: https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home

I.2)Information about joint procurement

I.3)Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home

Tenders or requests to participate must be submitted to the abovementioned address

I.4)Type of the contracting authority

Body governed by public law

I.5)Main activity

Education

Section II: Object

II.1)Scope of the procurement

II.1.1)Title:

QUB/1850/20 Contract for Clinical Research Services (Clinical Research Organisation)

Reference number: QUB/1850/20 A

II.1.2)Main CPV code

73110000

II.1.3)Type of contract

Services

II.1.4)Short description:

Queen’s University Belfast seeks to appoint a clinical research organisation (CRO) to provide services in respect of conducting a multinational Phase II study in non-cystic fibrosis BE patients, sponsored by Novartis, across Europe. The trial will be jointly funded by Novartis and the EU Innovative Medicines Initiative (IMI) through the iABC consortium. IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients (http://www.imi.europa.eu/). Access to tender documentation is restricted to those companies who download, complete and submit a CDA to Queen’s.

II.1.5)Estimated total value

II.1.6)Information about lots

This contract is divided into lots: no

II.2)Description

II.2.1)Title:

II.2.2)Additional CPV code(s)

73111000

73110000

85145000

85142000

II.2.3)Place of performance

NUTS code: IT

NUTS code: PT

NUTS code: BE

NUTS code: FR

NUTS code: UK

NUTS code: AT

NUTS code: CH

NUTS code: DE

NUTS code: IE

NUTS code: DK

NUTS code: NL

NUTS code: ES

Main site or place of performance:

The CRO must have the capability to manage a study across multiple EU countries.

II.2.4)Description of the procurement:

Queen’s University Belfast seeks to appoint a clinical research organisation (CRO) to provide services in respect of conducting a multinational Phase II study, sponsored by Novartis, across Europe.

II.2.5)Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6)Estimated value

II.2.7)Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: yes

Description of renewals:

Option to extend by up 2 years.

II.2.10)Information about variants

Variants will be accepted: no

II.2.11)Information about options

Options: yes

Description of options:

Two years with the option to extend by up 2 years.

II.2.12)Information about electronic catalogues

II.2.13)Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: yes

Identification of the project:

http://www.imi.europa.eu/

II.2.14)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

III.1.2)Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3)Technical and professional ability

Selection criteria as stated in the procurement documents

III.1.5)Information about reserved contracts

III.2)Conditions related to the contract

III.2.1)Information about a particular profession

III.2.2)Contract performance conditions:

The CRO must be capable of conducting a randomised phase II clinical study across Europe.

III.2.3)Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1)Description

IV.1.1)Type of procedure

Open procedure

Accelerated procedure

Justification:

Queen’s will be availing of Article 27 (3), Public Contracts Regulations 2015; where a state of urgency duly substantiated by the contracting authority renders impracticable the time limit laid down in the second subparagraph of paragraph 1, it may fix a time limit which shall be not less than 15 days from the date on which the contract notice was sent. Requirement was previously tendered under QUB/1850/19, OJEU Reference 2019/S 221-542205.

IV.1.3)Information about a framework agreement or a dynamic purchasing system

IV.1.4)Information about reduction of the number of solutions or tenders during negotiation or dialogue

IV.1.6)Information about electronic auction

IV.1.8)Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2)Administrative information

IV.2.1)Previous publication concerning this procedure

IV.2.2)Time limit for receipt of tenders or requests to participate

Date: 07/02/2020

Local time: 16:00

IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4)Languages in which tenders or requests to participate may be submitted:

English

IV.2.6)Minimum time frame during which the tenderer must maintain the tender

IV.2.7)Conditions for opening of tenders

Date: 07/02/2020

Local time: 16:15

Place:

Section VI: Complementary information

VI.1)Information about recurrence

This is a recurrent procurement: yes

VI.2)Information about electronic workflows

VI.3)Additional information:

Economic operators seeking to obtain tender documentation, must first download, complete and submit a confidential disclosure agreement (CDA). Tender documents will not be issued until a completed CDA has been received via correspondence on Intend.

VI.4)Procedures for review

VI.4.1)Review body

Official name: Queen’s University Belfast
Postal address: University Road
Town: Belfast
Postal code: BT7 1NN
Country: United Kingdom
E-mail: procurement@qub.ac.uk

VI.4.2)Body responsible for mediation procedures

VI.4.3)Review procedure

Precise information on deadline(s) for review procedures:

VI.4.4)Service from which information about the review procedure may be obtained

VI.5)Date of dispatch of this notice:

23/01/2020

Clinical Research Services Contract

Related posts: